The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck
Stock and Other Ownership Interests - Agenus; Celgene; Celldex; Endocyte; Macrogenics; Merck; Pharmacyclics
Research Funding - Merck KGaA
Patents, Royalties, Other Intellectual Property - Merck
KEYNOTE-177: Randomized phase III study of pembrolizumab versus investigator-choice chemotherapy for mismatch repair-deficient or microsatellite instability-high metastatic colorectal carcinoma.
 
Luis A. Diaz
Leadership - Personal Genome Diagnostics
Stock and Other Ownership Interests - PapGene, Inc.; Personal Genome Diagnostics
Consulting or Advisory Role - Genentech; Merck; Personal Genome Diagnostics
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - PapGene, PGDx and other entities have licensed several patent applications from Johns Hopkins, where Dr. Diaz is an inventor. These relationships are subject to certain restrictions under Johns Hopkins University policy, and the terms of these arrangement
Travel, Accommodations, Expenses - Merck
 
Dung T. Le
Honoraria - Merck
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Merck
 
Takayuki Yoshino
Research Funding - Sumitomo Dainippon
 
Thierry Andre
Honoraria - Amgen; Baxter; BAYER; Bristol-Myers Squibb; Lilly; Merck Serono; Roche/Genentech; Sanofi
Consulting or Advisory Role - Roche/Genentech
Travel, Accommodations, Expenses - Amgen; Roche/Genentech
 
Johanna C. Bendell
Research Funding - Apexigen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst)
 
Minori Koshiji
Employment - Merck
 
Yinghua Zhang
Employment - Merck
Stock and Other Ownership Interests - Merck
Research Funding - Merck
 
S. Peter Kang
No Relationships to Disclose
 
Baohoang Lam
No Relationships to Disclose
 
Dirk Jäger
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Roche